Any current/future new fundraising through debt or equity?

The company has recently raised Rs. 180 crores through equity shares and Rs. 370 crores through warrants to promoters and institutional investors, with Rs. 272 crores already received. Out of the funds raised, Rs. 198 crores have been utilized for debt repayment so far. The management has a strong focus on deleveraging and aims to become a long-term debt-free company within the next 18 months. Currently, they do not anticipate needing significant external capital for growth and are actively repaying debts. There is no mention of any planned new fundraising through debt or equity in the near fu

Any current/future capex/capital investment/strategic investment?

The company has a planned CAPEX of Rs. 670 crores, with Rs. 381 crores incurred in the first 9 months of FY '24. The remaining CAPEX is expected to be completed in the next two quarters, likely by the first half of FY '25. Post this large CAPEX, future expenditure will primarily be maintenance CAPEX with no new major CAPEX planned currently. The completed CAPEX will support revenue growth for the next 2-3 years, with capacity deemed sufficient for current and near-future demand. Investment in a 9.6 MW hybrid power plant (5.6 MW wind, 4 MW solar) with Rs. 59 crores planned, aimed at reducing en

Future growth expectations in sales/revenue/volumes?

Growth expected to pick up strongly from FY 2025 onwards after a subdued FY 2024 due to inventory realignment by customers. LOIs (Letters of Intent) and long-term contracts show robust customer engagement and are expected to contribute significantly to revenue growth in FY 2025 and FY 2026. New product launches, especially in pharma, polymers, and fluorination segments, will drive meaningful incremental volumes and revenue. Existing capacity can support revenue growth up to Rs. 1,700-1,800 crores; recent and upcoming CAPEX of Rs. 670 crores to be completed by H1 FY 2025 will enable servicing g

Future growth expectations in earnings/operating earnings/profits/EPS?

Growth expected to pick up from FY 2025, driven by new product launches and LOI commercialization (Page 16). Robust demand growth anticipated for next 2-3 years post FY 2025 due to order pipeline and new products (Page 12). Historical products provide revenue stability; pharma and polymer sectors expected to contribute meaningfully to growth in FY 25 and FY 26 (Page 7). EBITDA margins remain stable around 27-30%, with the business model focusing on EBITDA rather than gross margin (Page 16, Page 6). Interest savings of approximately Rs. 24 crores expected in FY 2025 due to debt repayment (Page

Current/ Expected Orderbook/ Pending Orders?

The company has signed several Letters of Intent (LOIs) and contracts with robust customer engagement and strong interest for long-term demand. Most of the LOIs are expected to commercialize within the next two years (2024–2026). Existing capacities can support revenue of Rs. 1,700-1,800 crores; no expected capacity constraints. New CAPEX of Rs. 670 crores is underway, expected to complete by first half of FY '25, boosting capacity for the next 2-3 years. Demand for contracted business has been subdued in the short term due to inventory de-stocking and client realignment. Recovery and growth i

IN US

Sale is live|00:00:00left today

Anupam Rasayan India LtdQ4 FY25Chemicals & Petrochemicals

Anupam Rasayan India Ltd Q4 FY25 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹1,266P/E: 91.1Market Cap: ₹15.7K CrSector: Chemicals & Petrochemicals

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

Yes

Order

Yes

Capex

2 of 5 growth signals are positive.

Full analysis

Revenue guidance

Category 3

→Growth expected to pick up strongly from FY 2025 onwards after a subdued FY 2024 due to inventory realignment by customers.
→LOIs (Letters of Intent) and long-term contracts show robust customer engagement and are expected to contribute significantly to revenue growth in FY 2025 and FY 2026.
→New product launches, especially in pharma, polymers, and fluorination segments, will drive meaningful incremental volumes and revenue.
→Existing capacity can support revenue growth up to Rs. 1,700-1,800 crores; recent and upcoming CAPEX of Rs. 670 crores to be completed by H1 FY 2025 will enable servicing growth for the next 2-3 years.
→Pharma expected to contribute double-digit growth; polymer and specialty chemicals to contribute 15-20% revenue share in FY 2025.
→Growth expected from both historical products (providing stability) and new molecules commercialized in the past two years (currently in teens percentage revenue contribution and rising).
→Demand momentum projected to resume and sustain growth beyond FY 2025.

Margin guidance

Category 3

→Growth expected to pick up from FY 2025, driven by new product launches and LOI commercialization (Page 16).
→Robust demand growth anticipated for next 2-3 years post FY 2025 due to order pipeline and new products (Page 12).
→Historical products provide revenue stability; pharma and polymer sectors expected to contribute meaningfully to growth in FY 25 and FY 26 (Page 7).
→EBITDA margins remain stable around 27-30%, with the business model focusing on EBITDA rather than gross margin (Page 16, Page 6).
→Interest savings of approximately Rs. 24 crores expected in FY 2025 due to debt repayment (Page 8).
→Capacity expansions through Rs. 670 crore CAPEX planned to complete by H1 FY 2025, supporting growth and ensuring no capacity constraints (Page 16).
→Working capital optimization is a management focus to support cash flow and growth (Page 12).

3 more insights locked — sign up free to unlock

Fundraise plans

Yes

→The company has recently raised Rs. 180 crores through equity shares and Rs. 370 crores through warrants to promoters and institutional investors, with Rs. 272 crores already received.
→Out of the funds raised, Rs. 198 crores have been utilized for debt repayment so far.
→The management has a strong focus on deleveraging and aims to become a long-term debt-free company within the next 18 months.
→Currently, they do not anticipate needing significant external capital for growth and are actively repaying debts.
→There is no mention of any planned new fundraising through debt or equity in the near future.
→Maintenance and remaining CAPEX of Rs. 289 crores (out of a total Rs. 670 crores planned) will be funded from existing cash and resources, with Rs. 577 crores in cash available as of December 31, 2023.

Order book

Yes

→The company has signed several Letters of Intent (LOIs) and contracts with robust customer engagement and strong interest for long-term demand.
→Most of the LOIs are expected to commercialize within the next two years (2024–2026).
→Existing capacities can support revenue of Rs. 1,700-1,800 crores; no expected capacity constraints.
→New CAPEX of Rs. 670 crores is underway, expected to complete by first half of FY '25, boosting capacity for the next 2-3 years.
→Demand for contracted business has been subdued in the short term due to inventory de-stocking and client realignment.
→Recovery and growth in orders are expected from Q1 FY '25, with FY '25 projected as a strong growth year.
→Pharma and polymer portfolios, supported by new molecules, should contribute significantly to order book growth.
→Contracts typically include a minimum guaranteed offtake with potential upsides, reducing risk of volume loss.

Capex plans

→The company has a planned CAPEX of Rs. 670 crores, with Rs. 381 crores incurred in the first 9 months of FY '24.
→The remaining CAPEX is expected to be completed in the next two quarters, likely by the first half of FY '25.
→Post this large CAPEX, future expenditure will primarily be maintenance CAPEX with no new major CAPEX planned currently.
→The completed CAPEX will support revenue growth for the next 2-3 years, with capacity deemed sufficient for current and near-future demand.
→Investment in a 9.6 MW hybrid power plant (5.6 MW wind, 4 MW solar) with Rs. 59 crores planned, aimed at reducing energy costs by approximately Rs. 15 crores annually.
→Strategic focus includes strengthening capacities, especially in fluorination, and expanding into pharma, polymer, and agro segments.
→The company is focused on deleveraging, aiming to become long-term debt-free over the next 18 months.

How does Anupam Rasayan India Ltd rank vs peers in Chemicals & Petrochemicals?

Pro feature

1Anupam Rasayan India Ltd

Rev 3Mar 3

See full Chemicals & Petrochemicals sector rankings

Want more stocks like Anupam Rasayan India Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio